Eisai R&d Management Co., Ltd.

Eisai Company, Limited

Eisai Inc.

Bruce Decosta

John JianShi Wang

Yimin Jiang

Xiang-Yi Li

Toshihiko Kaneko

Mark Spyvee

Seiichi Kobayashi

Kenzo Muramoto

Kouichi Kikuchi

Motohiro Soejima

Ieharu Hishinuma

Heather Davis

Boris M Seletsky

Wanjun Zheng

André Lescarbeau

Huiming Zhang

Norihito Ohi

Hong Du

Fabian Gusovsky

Hiromitsu Yokohama

Kenichi Nomoto

John (Yuan) Wang

Sergei I Agoulnik

Marc Pesant

Ye Yao

Jane Daun

Lynda Tremblay

Yan (Janet) Zhao

Francis Gerard Fang

Lynn D Hawkins

Kuo-Ming Wu

Xiang Niu

James E Foy

Charles Lemelin

Jiayi Wu

John (yuan) Wang

The present invention provides compounds, pharmaceutical compositions and methods for the treatment of specific cancers. Such compositions may generally comprise a compound of formula (I): wherein R-Rare as defined herein, or pharmaceutically acceptable salts or esters thereof; and a pharmaceutically acceptable carrier.

Multikinase inhibitors for use in the treatment of cancer

The present invention provides compounds, pharmaceutical compositions and methods for the treatment of specific cancers. Such compositions may generally comprise a compound of formula (I): 

The present invention provides compounds having formula (I): 

Deazapurines and uses thereof

This invention relates to the synthesis for a precursor of E6020, compound 26, via a &#x3b2;-keto amide alcohol intermediate, compound 22. The synthesis reacts compound 22 with compound 25 and the resultant intermediate is oxidized to produce compound 26, the precursor to E6020. Compounds 22 and 25, and their crystalline forms, represent separate embodiments of the invention. The invention also relates to compounds of formulas (3) and (4) and processes for their preparation. The &#x3b2;-keto amide alcohol intermediate compound 22 is a compound of formula (3). Compound 25 is a compound of formula (4).

Reagents and methods for the beta-keto amide synthesis of a synthetic precursor to immunological adjuvant E6020

As discussed above, there remains a need for the development of novel therapeutic agents useful for treating inflammatory or autoimmune and proliferative diseases. The present invention provides novel compounds of general formula (I), and pharmaceutical compositions thereof, as described generally and in classes and subclasses herein, as well as methods of making and using such compounds.

The present invention provides compounds having formula (I), wherein R, R, Rand n are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof in the treatment of inflammatory or autoimmune and proliferative disorders and as inhibitors of cell adhesion molecule expression and inflammatory cytokine signal transduction generally 

Growing community of inventors

Salem, NH, United States of America

Bruce Decosta